Company intelligence / Profile preview

Fair Therapeutics

Utrecht, Utrecht, Netherlandsfairtherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Fair Therapeutics has completed enrollment in its pivotal Phase IIb CHOICES trial evaluating Diponecaftor, a novel CFTR triple modulator therapy, in adults with ultra-rare cystic fibrosis variants. The trial uses an organoid-based diagnostic to pre-select patients most likely to benefit from the therapy. Results are expected mid-2025.

Therapeutic areas: Rare Diseases
Modalities: Small molecules (CFTR modulators)
Industry: Biotech

Drug pipeline

3 assets

dirocaftor

2 more assets in the full pipeline.

Request access →

Partnerships

HIT-CF consortium participation for clinical trials

Beyond the preview

Go deeper on Fair Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fair Therapeutics.

Explore the full profile